- Home
- Â /Â Jazz Pharmaceuticals
Jazz Pharmaceuticals
Stock Price
$111.9
2024-10-29
Market Capitalization
$6.9 B
2024-10-29
Revenue
$3.8 B
FY, 2023
Jazz Pharmaceuticals Summary
Company Summary
- Overview
- Jazz Pharmaceuticals is an international biopharmaceutical company. It offers Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Dublin, IE | view all locations
- Website
- https://www.jazzpharma.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Renée Galá, Executive Vice President and Chief Financial Officer
Robert Iannone, Executive Vice President, Global Head of Research and Development
Paul L. Berns, Director
LocationsView all
14 locations detected
Dublin, County Dublin HQ
Ireland
Waterloo Exchange, Waterloo Road
Carlsbad, CA
United States
5750 Fleet St #200
Palo Alto, CA
United States
3170 Porter Dr
Philadelphia, PA
United States
2005 Market St #2100
Mississauga, ON
Canada
602-4080 Confederation Pkwy
Vancouver, BC
Canada
250-887 Great Northern Way
Jazz Pharmaceuticals Financials
Summary Financials
- Revenue (Q3, 2024)
- $1.1B
- Net income (Q3, 2024)
- $215.1M
- Cash (Q3, 2024)
- $2.2B
- EBIT (Q3, 2024)
- $260.2M
- Enterprise value
- $10.8B